1. Delacretaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med 2006; 354(10): 1039-51.
2. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol 1998; 31(1): 150-7.
3. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136(1-2): 355-60.
4. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251(2): 471-6.
5. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74(1): 34-41.
6. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107(2): 198-211.
7. Masri B, Knibiehler B, Audigier Y. Apelin signalling: A promising pathway from cloning to pharmacology. Cell Signal 2005; 17(4): 415-26.
8. Kazemi-Bajestani SM, Patel VB, Wang W, Oudit GY. Targeting the ACE2 and apelin pathways are novel therapies for heart failure: Opportunities and challenges. Cardiol Res Pract 2012; 2012: 823193.
9. Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007; 357(4): 889-95.
10. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006; 27(2): 222-6.
11. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Goudis CA, Maliaraki NE, et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic Peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol 2010; 105(1): 90-4.
12. Falcone C, Buzzi MP, D'Angelo A, Schirinzi S, Falcone R, Rordorf R, et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 2010; 23(3): 917-25.
13. Gurger M, Celik A, Balin M, Gul E, Kobat MA, Bursali KB, et al. The association between apelin-12 levels and paroxysmal supraventricular tachycardia. J Cardiovasc Med (Hagerstown) 2014; 15(8): 642-6.
14. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: Clinical and experimental evidence. Eur Heart J 2006; 27(5): 512-8.
15. De Mello WC, Monterrubio J. Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart. Hypertension 2004; 44(3): 360-4.
16. Askari AT, Shishehbor MH, Kaminski MA, Riley MJ, Hsu A, Lincoff AM. The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V. Am Heart J 2009; 158(2): 238-43.
17. Ferron L, Capuano V, Ruchon Y, Deroubaix E, Coulombe A, Renaud JF. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res 2003; 93(12): 1241-8.
18. Zankov DP, Omatsu-Kanbe M, Isono T, Toyoda F, Ding WG, Matsuura H, et al. Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation 2006; 113(10): 1278-86.
19. Ashley E, Chun HJ, Quertermous T. Opposing cardiovascular roles for the angiotensin and apelin signaling pathways. J Mol Cell Cardiol 2006; 41(5): 778-81.
20. Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama K, et al. Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res 2011; 34(6): 701-6.
21. Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail 2010; 16(7): 556-61.
22. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011; 29(5): 971-9.
23. Tycinska AM, Lisowska A, Musial WJ, Sobkowicz B. Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta 2012; 413(3-4): 406-10.
24. Pan CS, Teng X, Zhang J, Cai Y, Zhao J, Wu W, et al. Apelin antagonizes myocardial impairment in sepsis. J Card Fail 2010; 16(7): 609-17.
25. Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007; 9(3): 306-9.
26. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369(9568): 1208-19.
27. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42(10): 1785-92.
28. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101(23): 2678-81.
29. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106(3): 331-6.
30. Churchill PC, McDonald FD, Churchill MC. Effect of diltiazem, a calcium antagonist, on renin secretion from rat kidney slices. Life Sci 1981; 29(4): 383-9.
31. Roy MW, Guthrie GP Jr, Holladay FP, Kotchen TA. Effects of verapamil on renin and aldosterone in the dog and rat. Am J Physiol 1983; 245(4): E410-E416.